News
1,200-person phase 2 study aims at sustained clearance of hepatitis B surface antigen
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
The Second Affiliated Hospital of Chongqing Medical University has registered a phase 2 study, first posted on 1 October 2026, of a combination strategy whose goal is sustained loss of hepatitis B surface antigen — the outcome clinicians treat as the ideal endpoint of hepatitis B treatment. The record says fewer than 10% of patients reach that endpoint with the antiviral drugs used today, that the study builds on a clinical programme supported by China’s national infectious-disease research funding, and that it plans to enrol about 1,200 participants at one site. No results are posted yet.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — trial registry record (public domain in the United States); our own summary and a link to the registry record, data as posted on 6 October 2026.